Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Get Free Report)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $12.00, but opened at $11.71. Pieris Pharmaceuticals shares last traded at $11.30, with a volume of 14,761 shares traded.
Wall Street Analysts Forecast Growth
Separately, StockNews.com started coverage on Pieris Pharmaceuticals in a research report on Sunday. They set a “hold” rating for the company.
Read Our Latest Stock Analysis on Pieris Pharmaceuticals
Pieris Pharmaceuticals Stock Performance
Pieris Pharmaceuticals (NASDAQ:PIRS – Get Free Report) last posted its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($4.00) earnings per share for the quarter. Pieris Pharmaceuticals had a negative return on equity of 90.17% and a negative net margin of 57.33%. The company had revenue of $1.30 million for the quarter.
Hedge Funds Weigh In On Pieris Pharmaceuticals
A number of large investors have recently modified their holdings of PIRS. CM Management LLC raised its stake in shares of Pieris Pharmaceuticals by 18.1% during the 3rd quarter. CM Management LLC now owns 649,400 shares of the biotechnology company’s stock worth $194,000 after buying an additional 99,400 shares in the last quarter. Acadian Asset Management LLC increased its stake in Pieris Pharmaceuticals by 64.8% in the 3rd quarter. Acadian Asset Management LLC now owns 962,358 shares of the biotechnology company’s stock valued at $286,000 after purchasing an additional 378,339 shares in the last quarter. Finally, Summit Trail Advisors LLC purchased a new position in Pieris Pharmaceuticals in the 1st quarter valued at approximately $26,000. 40.11% of the stock is owned by hedge funds and other institutional investors.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.
Featured Articles
- Five stocks we like better than Pieris Pharmaceuticals
- What is the Hang Seng index?
- High-Yield Texas Instruments Could Hit New Highs Soon
- 3 Fintech Stocks With Good 2021 Prospects
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.